Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is strengthening its position in the market with continuing developments in its pipeline, expanding its specialty distributor network to over 40 countries by YE2026 and aiming to commercialize its product VYJUVEK internationally. The company's net cash and projected NPV for its product B-VEC in DEB treatment also showcase its strong financial standing. Despite potential competition in the market, Krystal's pipeline and progress in clinical trials present positive opportunities for the company's growth.

Krystal Biotech is currently in the commercialization stage, and while they have successfully launched their gene therapy product VYJUVEK in select overseas markets, the pricing negotiations in other countries may not be resolved until 2026 or 2027. Their other internal programs, such as KB407 for cystic fibrosis and KB801 in neurotrophic keratitis, have relatively low projected sales and a limited track record of success. Additionally, there are high risks in manufacturing and regulatory delays as well as potential competition from other companies in the gene therapy space. This overall uncertainty and lack of strong financial data contribute to a negative outlook for Krystal Biotech's stock.